Irving H. Fox

16.0k total citations · 6 hit papers
194 papers, 12.1k citations indexed

About

Irving H. Fox is a scholar working on Molecular Biology, Epidemiology and Genetics. According to data from OpenAlex, Irving H. Fox has authored 194 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Molecular Biology, 86 papers in Epidemiology and 48 papers in Genetics. Recurrent topics in Irving H. Fox's work include Biochemical and Molecular Research (92 papers), Inflammatory Bowel Disease (45 papers) and Cytomegalovirus and herpesvirus research (40 papers). Irving H. Fox is often cited by papers focused on Biochemical and Molecular Research (92 papers), Inflammatory Bowel Disease (45 papers) and Cytomegalovirus and herpesvirus research (40 papers). Irving H. Fox collaborates with scholars based in United States, Canada and France. Irving H. Fox's co-authors include William N. Kelley, Brian G. Feagan, Asit Parikh, Catherine Milch, William J. Sandborn, Bruce E. Sands, Serap Sankoh, Jean‐Frédéric Colombel, Paul Rutgeerts and Jing Xu and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Irving H. Fox

190 papers receiving 11.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine profile →
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

2013 2.0k citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
The safety of vedolizumab for ulcerative colitis and Crohn's disease

2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →
Treatment of Ulcerative Colitis with a Humanized Antibody to the α ₄ β ₇ Integrin

2005 535 citations Brian G. Feagan, Gordon R. Greenberg et al. New England Journal of Medicine profile →
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

2014 531 citations Bruce E. Sands, Brian G. Feagan et al. Gastroenterology profile →
The Role of Adenosine and 2'-Deoxyadenosine in Mammalian Cells

1978 444 citations Irving H. Fox et al. profile →

Peers

Countries citing papers authored by Irving H. Fox

Since Specialization

Citations

This map shows the geographic impact of Irving H. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irving H. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irving H. Fox more than expected).

Fields of papers citing papers by Irving H. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irving H. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irving H. Fox. The network helps show where Irving H. Fox may publish in the future.

Co-authorship network of co-authors of Irving H. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Irving H. Fox. A scholar is included among the top collaborators of Irving H. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irving H. Fox. Irving H. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The safety of vedolizumab for ulcerative colitis and Crohn's disease breakdown → 2016 ·Gut ·Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts, William J. Sandborn, Silvio Danese, Geert D’Haens, Remo Panaccione, Edward V. Loftus, Serap Sankoh, Irving H. Fox, Asit Parikh, Catherine Milch, Brihad Abhyankar, Brian G. Feagan	563
2	Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers 2016 ·Clinical Drug Investigation ·Maria Rosario, Timothy Wyant, Timothy Leach, Serap Sankoh, Catherine Scholz, Asit Parikh, Irving H. Fox, Brian G. Feagan	38
3	P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders 2014 ·Journal of Crohn s and Colitis ·B G Feagan, William J. Sandborn, Matthew D. Smyth, Serap Sankoh, A. Parikh, Irving H. Fox	8
4	P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6 2014 ·Journal of Crohn s and Colitis ·W. Sandborn, Brian G. Feagan, Walter Reinisch, Michael Smyth, Jing Xu, A. Parikh, Irving H. Fox	9
5	Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed breakdown → 2014 ·Gastroenterology ·Bruce E. Sands, Brian G. Feagan, Paul Rutgeerts, Jean‐Frédéric Colombel, William J. Sandborn, Richmond Sy, Geert D’Haens, Shomron Ben‐Horin, Jing Xu, Maria Rosario, Irving H. Fox, Asit Parikh, Catherine Milch, Stephen B. Hanauer	531
6	Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease 2013 ·Inflammatory Bowel Diseases ·Asit Parikh, Irving H. Fox, Timothy Leach, Jing Xu, Catherine Scholz, (unknown), Brian G. Feagan	70
7	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis breakdown → 2013 ·New England Journal of Medicine ·Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, William J. Sandborn, Gert Van Assche, Jeffrey Axler, Hyo Jong Kim, Silvio Danese, Irving H. Fox, Catherine Milch, Serap Sankoh, Tim Wyant, Jing Xu, Asit Parikh	2048
8	P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers 2012 ·Journal of Crohn s and Colitis ·Catherine Milch, (unknown), (unknown), (unknown), J Berger, Irving H. Fox	7
9	Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study 2011 ·Inflammatory Bowel Diseases ·Asit Parikh, Timothy Leach, Tim Wyant, Catherine Scholz, Serap Sankoh, Diane R. Mould, Terry Ponich, Irving H. Fox, Brian G. Feagan	182
10	Treatment of Ulcerative Colitis with a Humanized Antibody to the α ₄ β ₇ Integrin breakdown → 2005 ·New England Journal of Medicine ·Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N. Fedorak, Pierre Paré, John WD McDonald, (unknown), Albert Cohen, A. Hillary Steinhart, Steven B. Landau, Rasha Aguzzi, Irving H. Fox, Margaret K. Vandervoort	535
11	Properties of Adenotin Reconstituted into Phospholipid Vesicles 1991 ·The American Journal of the Medical Sciences ·Kevin A. Hutchison, Madhu Prasad, (unknown), Irving H. Fox	1
12	Soluble and membrane-associated human low-affinity adenosine binding protein (adenotin): properties and homology with mammalian and avian stress proteins 1990 ·Biochemistry ·(unknown), (unknown), Fulvio Perini, Irving H. Fox	46
13	Characteristics of an adenosine A1 binding site in human placental membranes 1989 ·Archives of Biochemistry and Biophysics ·(unknown), Kevin A. Hutchison, Madhu Prasad, Robert F. Bruns, Irving H. Fox	12
14	Properties of Highly Purified Human T Lymphoblast (Molt-4) Deoxycytidine Kinase 1989 ·Advances in experimental medicine and biology ·N S Datta, Donna S. Shewach, Mary C. Hurley, Beverly S. Mitchell, Irving H. Fox	1
15	Isocratic separation of ATP and its degradation products from biological fluids by automated liquid chromatography. 1988 ·Clinical Chemistry ·Kim K. Tekkanat, Irving H. Fox	37
16	Radiologic features of a pyrophosphate-like arthropathy associated with long-term dialysis 1987 ·Skeletal Radiology ·Ethan M. Braunstein, (unknown), William Martel, Richard D. Swartz, Irving H. Fox	15
17	Uric acid metabolism in patients receiving total parenteral nutrition (TPN). 1980 ·Gastroenterology ·John Lambert, Moshe Shike, Irving H. Fox, K.N. Jeejeebhoy	2
18	Normal B-lymphocyte function in patients with Lesch-Nyhan syndrome and HGPRT deficiency. 1978 ·PubMed Central ·Erwin W. Gelfand, Irving H. Fox, (unknown), Hans‐Michael Dosch	8
19	Hypouricemia in disease: a study of different mechanisms. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Isaac L. Dwosh, Daniel A. K. Roncari, Errol B. Marliss, Irving H. Fox	23
20	The Sixty-minute Plasma Phenolsulfonphthalein Concentration as a Test of Renal Function 1969 ·American Journal of Clinical Pathology ·(unknown), Irving H. Fox	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact